  |  |
| News
If you are a member of the media and have questions about Bayer in Canada, please contact Marija Mandic, Director of Communications, at marija.mandic@bayer.com, or 416-240-5376, or Emily Hanft, Senior Business Communications Partner, at emily.hanft@bayer.com, or 416-240-5466.
May 7, 2013
Saluting Canadian innovators who embody Bayer’s philosophy: Science for a Better Life
more
April 19, 2013
Bayer’s Xarelto® (rivaroxaban tablet) Now Approved for the Treatment of Venous Thromboembolic Events and Prevention of Recurrent
more
March 25, 2013
First New Colon Cancer Treatment Since 2006 Received Priority Review From Health Canada And Is Now Approved For Canadian...
more
November 26, 2012
Bayer Expands Leadership in Medical Information Technology through Acquisition of Toronto-based Radimetrics, Inc.
more
November 13, 2012
New Canadian-Led Global Study of Xarelto® (rivaroxaban tablet) Initiated in Patients with Coronary or Peripheral Artery Disease
more
October 17, 2012
Canadians in eight provinces now eligible for newly reimbursed treatment for stroke prevention in atrial fibrillation
more
October 15, 2012
Bayer’s Stivarga® (regorafenib) Tablets Approved by the U.S. FDA for the Treatment of Metastatic Colorectal Cancer
more
April 23, 2012
Once-daily oral anticoagulant receives positive Common Drug Review recommendation for stroke prevention in atrial fibrillation
more
February 21, 2012
Xarelto® Approved for the Treatment of Deep Vein Thrombosis without Symptomatic Pulmonary Embolism
more
December 1, 2011
Bayer Inc. Medical Statement: Safety of Hormonal Combined Oral Contraceptives (YAZ®, Yasmin®)
more
November 29, 2011
Visanne® is the first oral treatment approved in more than 10 years for Canadian women with endometriosis
more
Bayer Inc. Corporate Brochure